PsyMed Ventures invests in transformational technologies that elevate mental health and wellness through it's fund and angel syndicate.
Key people at PsyMed Ventures.
PsyMed Ventures is a venture capital firm dedicated to investing in transformational technologies that advance mental health and brain wellness. Their mission centers on funding founders who are revolutionizing brain and mental health through innovative neuroscience, frontier technologies, and psychedelic therapies, aiming to treat the root causes of mental health conditions rather than just symptoms. Their investment philosophy aligns healing, responsibility, and profitability, focusing on sectors such as neurotechnology, precision psychiatry, novel therapeutics, digital health, and alternative modalities. PsyMed Ventures supports early-stage companies that develop cutting-edge solutions like precision psychiatry platforms, CRISPR-based therapeutics, microbiome treatments, and novel drug formulations. Through its fund and angel syndicate, PsyMed Ventures plays a pivotal role in nurturing startups that are shaping the future of mental health care and wellness[1][2][3].
Founded in 2020 by Greg Kubin and Matias Serebrinsky, PsyMed Ventures emerged from the founders’ shared vision to build a community-focused fund dedicated to frontier brain and mental health technologies. Kubin and Serebrinsky bring complementary backgrounds in investment, entrepreneurship, and ecosystem building—Kubin with experience in community building and SaaS platforms, and Serebrinsky with a history in AI startup acceleration and foodtech. The firm has evolved to emphasize not only capital deployment but also active support through its network and content initiatives like the "Business Trip" podcast, which explores the emerging psychedelics industry and mental health innovation. This evolution reflects their commitment to both financial returns and advancing the mental health ecosystem[1][2][4][5].
PsyMed Ventures is riding the wave of increasing recognition that mental health requires innovative, science-driven solutions beyond traditional pharmaceuticals. The timing is critical as advances in neuroscience, AI, and biotechnology converge with growing societal demand for effective mental health treatments. Market forces such as rising mental health awareness, regulatory shifts favoring psychedelic therapies, and technological breakthroughs in precision medicine create a fertile environment for PsyMed’s investments. By backing companies that develop transformative therapies and technologies, PsyMed Ventures influences the broader ecosystem by accelerating the commercialization of frontier brain health innovations and fostering a new industry focused on healing and wellness[1][2][6].
Looking ahead, PsyMed Ventures is poised to expand its influence as mental health innovation continues to gain momentum globally. Trends such as AI-driven diagnostics, personalized neurotherapeutics, and the mainstreaming of psychedelic-assisted treatments will likely shape their investment focus. The firm’s community-driven approach and deep sector expertise position it to remain a key player in catalyzing the next generation of mental health solutions. As the mental health crisis intensifies worldwide, PsyMed Ventures’ commitment to aligning healing with profitability could redefine how mental health care is delivered and financed, potentially impacting millions of lives[1][2][4].
Key people at PsyMed Ventures.
